J&J, New York University pharmaceuticals news

Johnson & Johnson enlisted the university’s school of medicine to review compassionate use requests made to the pharma to access J&J products that are not yet approved. NYU will establish the Compassionate-Use Advisory Committee (CompAC), an independent committee, to make recommendations regarding individual patient requests worldwide. The 10-member committee will comprise medical experts, bioethicists and patient representatives.

CompAC will initially evaluate compassionate use requests for a single J&J compound, which the company declined to name. The pharma said the pilot program will likely continue through YE15 and will end when J&J launches the therapy. ...